![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » CMS Cuts 2018 340B Reimbursements to ASP Minus 22.5 Percent
CMS Cuts 2018 340B Reimbursements to ASP Minus 22.5 Percent
November 6, 2017
The Centers for Medicare and Medicaid Services reduced the amount Medicare Part B will pay hospitals for purchasing drugs through the 340B discount program — cutting reimbursements down to the average sales price minus 22.5 percent, rather than the previous ASP plus 6 percent — for the 2018 calendar year.
The expected $1.6 billion in savings generated from the final rule will be redistributed to other outpatient payments for items and services, and will help lower out-of-pocket drug costs for beneficiaries, CMS said. Drugs not purchased under the 340B drug program will continue to be paid at a rate of ASP plus 6 percent.
CMS said the move more closely aligns payments with the hospital acquisition costs for drugs and biologics purchased from manufacturers at the substantial discounts required under the 25-year-old program.
Upcoming Events
-
21Oct